---
figid: PMC2268054__bjp20081f1
figlink: /pmc/articles/PMC2268054/figure/fig1/
number: Figure 1
caption: Role of glycoprotein 130 (gp130) downstream signalling in the heart. Scheme
  of gp130 receptor activation showing interleukin-6 (IL-6) type cytokines binding
  to their transmembrane receptor α-subunits, which induces homodimerization of the
  gp130 receptor β-subunits or heterodimerization of gp130 with either one of the
  structurally and functionally similar leukaemia inhibitory factor (LIF) receptor
  and oncostatin M (OSM) receptor β-subunits. Following dimerization of the gp130
  receptor complex, Janus kinase-1/2 (JAK1/2) constitutively connected to the intracytoplasmatic
  membrane proximal regions of the receptor subunits are catalytically activated and
  themselves transphosphorylate tyrosine residues in the gp130 receptor intracellular
  domain. Subsequently, two major intracellular signalling cascades are triggered,
  the signal transducer and activator of transcription (STAT)-1/3 pathway and the
  SH2 domain-containing cytoplasmic protein tyrosine phosphatase (SHP2)/MEK/extracellular
  signal-regulated kinase (ERK) pathway. Via the formation of complexes with growth
  factor receptor binding protein-2 (Grb2)-associated binding protein-1/2 (Gab1/2)
  and phosphatidylinositol-3-kinase (PI3K), SHP2 activation furthermore initiates
  the Akt pathway and additionally enhances MEK/ERK signalling. Activation of gp130-mediated
  signalling plays essential roles in stem cells and cardiomyogenesis. In the adult
  heart, it is involved in numerous physiological and pathophysiological processes.
  MEK, mitogen-activated protein kinase (MAPK)/ERK kinase.
pmcid: PMC2268054
papertitle: Role of gp130-mediated signalling pathways in the heart and its impact
  on potential therapeutic aspects.
reftext: P Fischer, et al. Br J Pharmacol. 2008 Mar;153(Suppl 1):S414-S427.
pmc_ranked_result_index: '50502'
pathway_score: 0.9097518
filename: bjp20081f1.jpg
figtitle: Role of glycoprotein 130 (gp130) downstream signalling in the heart
year: '2008'
organisms: Homo sapiens
ndex: 849dd0fb-df0f-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2268054__bjp20081f1.html
  '@type': Dataset
  description: Role of glycoprotein 130 (gp130) downstream signalling in the heart.
    Scheme of gp130 receptor activation showing interleukin-6 (IL-6) type cytokines
    binding to their transmembrane receptor α-subunits, which induces homodimerization
    of the gp130 receptor β-subunits or heterodimerization of gp130 with either one
    of the structurally and functionally similar leukaemia inhibitory factor (LIF)
    receptor and oncostatin M (OSM) receptor β-subunits. Following dimerization of
    the gp130 receptor complex, Janus kinase-1/2 (JAK1/2) constitutively connected
    to the intracytoplasmatic membrane proximal regions of the receptor subunits are
    catalytically activated and themselves transphosphorylate tyrosine residues in
    the gp130 receptor intracellular domain. Subsequently, two major intracellular
    signalling cascades are triggered, the signal transducer and activator of transcription
    (STAT)-1/3 pathway and the SH2 domain-containing cytoplasmic protein tyrosine
    phosphatase (SHP2)/MEK/extracellular signal-regulated kinase (ERK) pathway. Via
    the formation of complexes with growth factor receptor binding protein-2 (Grb2)-associated
    binding protein-1/2 (Gab1/2) and phosphatidylinositol-3-kinase (PI3K), SHP2 activation
    furthermore initiates the Akt pathway and additionally enhances MEK/ERK signalling.
    Activation of gp130-mediated signalling plays essential roles in stem cells and
    cardiomyogenesis. In the adult heart, it is involved in numerous physiological
    and pathophysiological processes. MEK, mitogen-activated protein kinase (MAPK)/ERK
    kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - GAB1
  - PIK3CB
  - KRAS
  - PIK3R3
  - CTF1
  - NRAS
  - PIK3CG
  - HRAS
  - PIK3R4
  - AKT2
  - STAT3
  - JAK1
  - PIK3CA
  - AKT1
  - MAPK1
  - IL6
  - PIK3R5
  - JAK2
  - LIF
  - MAPK3
  - IL11
  - AKT3
  - FCGRT
  - PTPN11
  - OSM
  - RAF1
  - BRAF
  - GRB2
  - MAP2K1
  - PIK3CD
  - STAT1
  - PIK3R6
  - MAP2K2
  - ARAF
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: Gab1/2/PI3K
  symbol: GAB1
  source: hgnc_symbol
  hgnc_symbol: GAB1
  entrez: '2549'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: CT-1
  symbol: CT-1
  source: hgnc_alias_symbol
  hgnc_symbol: CTF1
  entrez: '1489'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: STAT1/3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: JAK1/2
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: JAK1/2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: LIF
  symbol: LIF
  source: hgnc_symbol
  hgnc_symbol: LIF
  entrez: '3976'
- word: MEK/ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: (IL-11
  symbol: IL11
  source: hgnc_symbol
  hgnc_symbol: IL11
  entrez: '3589'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: (a-chain)
  symbol: alpha-chain
  source: hgnc_alias_symbol
  hgnc_symbol: FCGRT
  entrez: '2217'
- word: SHP-2
  symbol: SHP-2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: OSM
  symbol: OSM
  source: hgnc_symbol
  hgnc_symbol: OSM
  entrez: '5008'
- word: Ras/Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras/Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Grb2
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: STAT1/3
  symbol: STAT1
  source: hgnc_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: Gab1/2/PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MEK/ERK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Ras/Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
